Loading
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Previous close
$4.87
−$0.02 · -0.41%
After-hours
$4.87
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Day range
Current $4.87
52-week range
Current $4.87
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
29
Expensive
Sentiment
60
Mixed
Risk
63
High Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Day range
Current $4.87
52-week range
Current $4.87
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.77M USD | 9.45M USD | 15.49M USD | 9M USD | 8.41M USD |
| Selling, general, and administrative | 10.16M USD | 6.2M USD | 7.27M USD | 8.51M USD | 12.27M USD |
| Operating expenses | 19.94M USD | 15.64M USD | 22.76M USD | 17.5M USD | 20.68M USD |
| Interest income | 369.27K USD | — | 775.76K USD | 174.51 USD | — |
| Interest expense | 924.45K USD | — | — | 174K USD | 33.41K USD |
| Depreciation and amortization | 540.89K USD | 653.09K USD | 582.92K USD | 394.01K USD | 708.32K USD |
| Operating income | −19.94M USD | −15.64M USD | −22.76M USD | −17.5M USD | −20.68M USD |
| Net income | −22.45M USD | −16.56M USD | −23.53M USD | −17.68M USD | −20.71M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.00
84.80% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 9, 2024 | 1:12 | — | — |
Stock split | Nov 30, 2023 | 1:20 | — | — |
Effective Aug 9, 2024
1:12
Effective Nov 30, 2023
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
